Eden Research has raised £10.8 million to support the next phase of its biopesticide business as regulatory approvals for its flagship products open new markets and applications.
The UK-based sustainable crop-protection company reported revenue of £4.9 million for the 15 months ended March 31, 2026, up from £4.3 million in calendar 2024. Its operating loss widened to £2.9 million from £2.2 million, while cash at the end of the reporting period stood at £1.5 million, compared with £3.7 million previously.
The fundraise, completed around the end of the financial period, provided £10.8 million in gross proceeds, with £7.6 million received after March 31. Part of the new capital is being directed toward 2026 field trials for late blight and septoria, two disease areas central to Eden’s pipeline.
Regulatory progress has meanwhile expanded the commercial footprint of the company’s products. Mevalone, its leading fungicide, received approval in California for controlling powdery mildew in grapes. France also authorised Mevalone for grape production against downy and powdery mildew, subject to restrictions. Eden sees the French approval as particularly significant because restrictions and bans on some incumbent crop-protection products could create room for alternative solutions.
In Italy, 3LOGY, known as Mevalone in most other markets, received approval for use on several additional crops against Botrytis and diseases including powdery mildew and Sclerotinia. The company also secured Chilean regulatory authorisation for Novellus+, an enhanced version of Mevalone.
Eden is expanding its distribution network alongside those regulatory gains. Andermatt Kenya has been appointed exclusive distributor for Mevalone in Kenya, while Syngenta Crop Protection has taken on exclusive distribution for professional applications in indoor and outdoor ornamental crops across several European countries and the UK.
Ecovelex, Eden’s bird-repellent seed-treatment product, also gained regulatory momentum. Italy granted temporary approval for Ecovelex during the 2025 season for use on maize for the 2026 growing season. The company expects future sales to benefit from additional approvals and temporary authorisations.
Beyond crop protection, Eden has signed an agreement with French pharmaceutical laboratory Veto-pharma to supply thymol for bee-health applications in the US. The company also reached a £0.4 million data-access agreement with associate company TerpeneTech covering Eden’s geraniol dossier. The data will support TerpeneTech’s continued role as a notified geraniol supplier under the EU Biocidal Products Regulations.
The commercial outlook, however, remains sensitive to weather. Demand for Mevalone is closely linked to disease pressure created by humidity and rainfall during the growing season. Prolonged hot and dry conditions in Europe and the US can reduce disease incidence, shorten treatment windows and lead to lower in-season applications and distributor reorders. Eden said the resulting impact on year-end sales and channel inventories will become clearer later in 2026.
The company is also pursuing its next product opportunity. Discussions are continuing with two potential partners for Eden’s insecticide product, with the company expecting to sign an agreement by the end of 2026.
Lykele van der Broek, Chairman of Eden Research, highlighted the French Mevalone approval as one of the most commercially important developments during the period. He said the product’s coverage of both downy and powdery mildew could allow Eden to capture a meaningful share of a sizeable market as existing products face restrictions.
Corteva Agriscience, Eden’s French partner for Mevalone, is working to establish the product in that market. Van der Broek said the opportunity could become a significant contributor to Eden’s future growth, while pointing to a broader pipeline of opportunities moving toward commercialisation.
For Eden, the combination of fresh capital, expanding regulatory clearances and a broader distribution network puts greater emphasis on converting its biopesticide technology into recurring international sales. The immediate challenge will be turning those approvals into market share while navigating weather-driven demand and the timing of distributor stocking cycles.
